Astra Aktiebolag

Aktiebolaget Astra

Eva Maria Hammarberg

Svante Bertil Ross

Lars George Johansson

Seth-Olov Thorberg

Daniel Dungan Sohn

Rolf Noreen

Lars-Gunnar Larsson

Bjorn Eric Svensson

Lucy Anna Renyi

Sven E Hellberg

John L Evenden

Seth O Thorberg

Hans S Hansson

Johan R Lundkvist

3-amino-5-carbonylchromans, as well as enantiomers and salts thereof are disclosed. Pharmaceutical compositions containing the compounds as active ingredients are also disclosed. The compounds are useful in the treatment of 5-hydroxytryptamine-mediated disorders of the central nervous system.

Chroman derivatives

A method is disclosed for the treatment of anxiety by the administration of 3-amino-5-carbamoyl-chromans and 8-fluoro-3-amino-5-carbamoylchromans or enantiomers or salts thereof.

Method for the treatment of anxiety

Compounds of the formula ##STR1## are disclosed. These compounds are employed as intermediates in the synthesis of aminochroman compounds useful in the treatment of CNS disorders.

Intermediates in the synthesis of chroman derivatives

A method is disclosed for the treatment of depression by the administration of 3-amino-5-carbamoylchromans and 8-fluoro-3-amino-5-carbamoylchromans or enantiomers or salts thereof.

Method for the treatment of depression

3-amino-5-aryl- and 5-heteroarylchromans, as well as enantiomers and salts thereof are disclosed. Pharmaceutical compositions containing the compounds as active ingredients are also disclosed. The compounds are useful in the treatment of 5-hydroxytryptamine-mediated disorders of the central nervous system.

A method is disclosed for the treatment of migraine by the administration of 3-amino-5-carbamoyl-chromans and 8-fluoro-3-amino-5-carbamoylchromans or enantiomers or salts thereof.

Method for the treatment of migraine

(R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzo

3-amino-5-carbamoylchromans and 8-fluoro-3-amino-5-carbamoylchromans, as well as enantiomers and salts thereof, are disclosed. Pharmaceutical compositions containing the compounds as active ingredients are also disclosed. The compounds are useful in the treatment of 5-hydroxytryptamine-mediated disorders of the central nervous system.

Growing community of inventors

Sodertalje, Sweden

Eva Maria Hammarberg